Targeted therapies: Imatinib prior to allogeneic HSCT therapy improves both relapse and nonrelapse survival in patients with Ph+ ALL
- PMID: 24642681
- DOI: 10.1038/nrclinonc.2014.48
Targeted therapies: Imatinib prior to allogeneic HSCT therapy improves both relapse and nonrelapse survival in patients with Ph+ ALL
Comment on
-
Pretransplant administration of imatinib for allo-HSCT in patients with BCR-ABL-positive acute lymphoblastic leukemia.Blood. 2014 Apr 10;123(15):2325-32. doi: 10.1182/blood-2013-11-538728. Epub 2014 Mar 3. Blood. 2014. PMID: 24591204
References
-
- Blood. 2014 Apr 10;123(15):2325-32 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
